NCT01447927View on ClinicalTrials.gov

Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

September 30, 2013

Conditions
Barrett EsophagusEsophageal Cancer
Interventions
DRUG

metformin hydrochloride

Given PO QD and BID

OTHER

placebo

Given PO QD and BID

Trial Locations (7)

15232

University of Pittsburgh Medical Center - Shadyside Hospital, Pittsburgh

44106

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

55905

Mayo Clinic, Rochester

60141

Hines Veterans Administration Hospital, Hines

44106-5065

Case Comprehensive Cancer Center, Cleveland

M5S 1A1

University of Toronto, Toronto

00936

University of Puerto Rico, San Juan

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01447927 - Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus | Biotech Hunter | Biotech Hunter